CLDN1 and incontinentia pigmenti: The primary outcome was to investigate the variations in IP status in the two study groups by considering a well-validated panel of stool-assessable and circulating markers (fecal zonulin, serum occludin, serum claudin-1, and serum LPBp) in a dysmetabolic setting [13] as well as in the proportion of patients who achieved an improvement in IP after 12 months.